M

    Mink Therapeutics Inc (INKT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $11.09
    -0.34 (-2.96%)

    Market Cap: $58.32M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    67%(14/21)
    Avg Surprise
    -31.30%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.35
    Range$-0.35 - $-0.35
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.91-160.0%
    60d ago$-0.63-80.0%
    30d ago$-0.63-80.0%
    7d ago$-0.63-80.0%
    Current$-0.35
    Revenue Consensus
    $2M
    Range$2M - $2M
    1 analysts
    Dec 31, 2026
    EPS Consensus$-0.21
    Range$-0.21 - $-0.21
    1 analysts
    Revenue Consensus
    $2M
    Range$2M - $2M
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.21---
    Sep 26EST
    		-$-0.35---
    Jun 26
    		$-0.62$-0.60-3.33%Miss+41.5%
    Mar 26
    		$-0.57$-0.77+25.97%Beat+18.6%
    Dec 25
    		$-0.56$-0.68+17.65%Beat+9.7%
    Sep 25
    		$-0.65$-0.85+23.53%Beat-30.0%
    Jun 25
    		$-1.06$-0.55-92.73%Miss-51.4%
    Mar 25
    		$-0.70$-0.61-14.75%Miss+36.4%
    Dec 24
    		$-0.62$-0.08-675.00%Miss-287.5%
    Sep 24
    		$-0.50$-0.80+37.50%Beat+66.7%
    Jun 24
    		$-0.70$-0.97+27.84%Beat+61.1%
    Mar 24
    		$-1.10$-1.53+28.10%Beat+35.3%
    Dec 23
    		$-0.16$-0.15-6.67%Miss+30.4%
    Sep 23
    		$-1.50$-1.82+17.58%Beat+21.1%
    Jun 23
    		$-1.80$-1.97+8.63%Beat+0.0%
    Mar 23
    		$-1.70$-2.37+28.27%Beat+26.1%
    Dec 22
    		$-0.23$-0.21-9.52%Miss-27.8%
    Sep 22
    		$-1.90$-2.33+18.45%Beat+67.8%
    Jun 22
    		$-1.80$-2.40+25.00%Beat-757.1%
    Mar 22
    		$-2.30$-2.30+0.00%Beat-992.1%
    Dec 21
    		$-0.18N/A+56.10%Beat+14.5%
    Sep 21
    		$-5.90$-2.00-195.00%Miss-3658.0%
    Jun 21
    		$-0.21$-0.28+25.00%Beat-33.8%
    Mar 21
    		$-0.21$0.00N/AMiss-17.1%
    Dec 20
    		$-0.21$0.00N/AMiss-17.1%
    Sep 20
    		$-0.16$0.00N/AMiss-
    Jun 20
    		$-0.16$0.00N/AMiss-
    Mar 20
    		$-0.18$0.00N/AMiss-
    Dec 19
    		$-0.18$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-4.62EV/EBITDA-3.67x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-1239.00%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage36.49x
    Current Ratio1.23xQuick Ratio1.23x
    Trading Statistics
    Beta0.48Avg Volume9.16K
    52-Week High$16.9852-Week Low$8.48

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$11.61
    SMA 20$11.39
    SMA 50$11.23
    SMA 200$11.40
    EMA 10$11.47
    EMA 20$11.38
    EMA 50$11.30
    EMA 200$11.49

    MACD

    Line: 0.11Signal: 0.13Hist: -0.02

    ADX

    ADX: 30.9+DI: 21.5-DI: 13.2

    Aroon & PSAR

    Aroon Up80.0
    Aroon Down4.0
    PSAR$12.15

    Bollinger Bands

    Upper Band$12.14
    Lower Band$10.65
    %B Position1306%(Upper)
    Band Width0.30

    RSI (14-Day)

    Neutral
    47.3

    Momentum Oscillators

    Stoch %K41.0
    Stoch %D51.8
    Williams %R-81.0
    ROC (10d)-1.2%
    Momentum-0.13
    CCI (20d)-35.9
    MFI (14d)53.3

    Volatility Measures

    ATR (14d)$0.65(5.9%)
    StdDev (20d)0.37
    Hist Vol63.1%(High)

    Volume Flow

    VWAP$11.27
    OBV55.6M
    AD Line9.9M
    CMF (20d)0.116

    Volume Metrics

    Avg Vol (20d)9.3K
    Vol Ratio1.3x
    VWMA (20d)$11.41

    Pivot Points

    R3$11.96
    R2$11.70
    R1$11.57
    Pivot Point$11.31
    S1$11.18
    S2$10.92
    S3$10.79

    Advanced Oscillators

    TSI4.62
    Ultimate Osc58.4
    KST58.36

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$3.77B$0$0$0$-11,708,192,000$0
    Cost of Revenue$0$0$38,563$0$0$0$53,869$0$0$0$53,572$0
    Gross Profit$0$0$-38,563$0$0$0$-53,869$0$0$0$-53,572$0
    Operating Expenses$3.22M$2.88M$2.71M$3.18M$4.05M$2.70M$2.50M$1.88M$3.07M$3.83M$5.50M$5.22M
    R&D$1.89M$1.20M$1.51M$1.14M$1.84M$1.26M$1.41M$540,638$1.84M$2.55M$3.31M$3.43M
    SG&A$1.33M$1.68M$1.76M$1.85M$1.85M$1.27M$808,906$1.16M$1.06M$1.28M$2.19M$1.80M
    Operating Income$-3,216,894$-2,881,787$-2,705,459$-3,183,594$-4,052,396$-2,700,687$-2,502,678$-1,884,612$-3,071,081$-3,829,914$-5,500,104$-5,223,561
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$-72,884$-80,834$-111,230$-55,151$-348$-13,517$-39,574$-78,015$-38,360$-16,619$-41,525$-107,287
    Income Before Tax$-3,128,201$-2,742,368$-2,602,103$-2,887,709$-4,237,751$-2,766,697$-2,463,104$-1,806,597$-2,701,806$-3,813,295$-5,458,597$-5,116,266
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-3,128,201$-2,742,368$-2,602,103$-2,887,709$-4,237,751$-2,766,697$-2,463,104$-1,806,597$-2,701,806$-3,813,295$-5,458,597$-5,116,266
    EBITDA$-3,165,021$-2,787,136$-2,674,770$-2,899,206$-4,189,336$-2,729,449$-2,448,809$-1,821,975$-2,695,066$-3,776,083$-5,446,550$-5,170,100
    EBIT$-3,201,085$-2,823,202$-2,713,333$-2,942,860$-4,238,099$-2,780,214$-2,502,678$-1,884,612$-2,740,166$-3,829,914$-5,500,122$-5,223,553
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about INKT

    News

    Q3 EPS Estimate for MiNK Therapeutics Boosted by Analyst

    HC Wainwright has increased its Q3 2026 EPS estimate for MiNK Therapeutics (NASDAQ: INKT) to a loss of $0.35 per share, up from a previous estimate of $0.63, while maintaining a "Buy" rating and a $35 price target. This adjustment comes after MiNK Therapeutics reported a quarterly loss of $0.62 per share, slightly missing the consensus estimate of $0.60. Despite the boosted EPS estimate, analysts currently hold an overall "Hold" rating for the stock, with an average target price of $35.

    MarketBeat•8/18/26•
    Somewhat-Bullish

    MiNK Therapeutics Q2 2026 Earnings Call: Complete Transcript

    MiNK Therapeutics reported on its Q2 2026 earnings call, highlighting the advancement of Agent 797 into a randomized Phase 2 study for acute lung injury and ARDS, with initial positive observations. The company also launched its first international named patient access program in Brazil and maintained financial discipline with a narrowed net loss of $3.1 million. Strategic priorities include expanding U.S. study sites and generating further clinical data for Agent 797.

    Sahm•8/14/26•
    Bullish

    H.C. Wainwright Maintains MiNK Therapeutics(INKT.US) With Buy Rating, Maintains Target Price $35

    H.C. Wainwright has reiterated its Buy rating for MiNK Therapeutics (INKT.US), maintaining a price target of $35. This indicates the firm's continued positive outlook on the company's stock performance.

    Moomoo•8/14/26•
    Bullish

    MiNK Therapeutics (NASDAQ:INKT) Stock Rating Lowered by Zacks Research

    Zacks Research has downgraded MiNK Therapeutics (NASDAQ:INKT) from a "strong-buy" to a "hold" rating, aligning with the broader analyst consensus and an average price target of $35.00. The clinical-stage biotechnology company, specializing in exosome-based immunotherapies, saw its shares open at $11.00 after reporting a quarterly loss of $0.62 per share, missing estimates. Institutional ownership remains low at 2.87%, though DRW Securities recently acquired a new stake.

    MarketBeat•8/14/26•
    Bearish

    Initial ventilated patients treated in MiNK's trial were alive at Day 28

    MiNK Therapeutics reported its Q2 2026 financial results, including a narrowed net loss of $3.1 million. The company also provided an update on its randomized Phase 2 trial for agenT-797 in acute lung injury/ARDS, noting that initial ventilated patients were alive at Day 28 with improved respiratory status and no major adverse events attributed to the therapy. Additionally, MiNK launched a paid named-patient access program in Brazil for agenT-797 to provide access and build cross-border infrastructure.

    Stock Titan•8/14/26•
    Somewhat-Bullish

    Frequently Asked Questions About INKT

    Does INKT pay dividends?
    Mink Therapeutics Inc (INKT) does not currently pay a regular dividend.
    What is INKT's market cap?
    Mink Therapeutics Inc (INKT) has a market capitalization of $58.32M with a current stock price of $11.09.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In